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Abstract 
Background: Health messages on e-cigarette packs emphasise nicotine addiction or harms using similar wording to 
warnings on cigarette packs. These may not be appropriate for e-cigarettes which constitute a reduced risk alternative 
for smokers. This research aimed to (1) develop and test a selection of relative risk messages for e-cigarette products; 
(2) compare these to the two current EU Tobacco Products Directive (TPD) nicotine addiction messages; and (3) 
explore differences between smokers, non-smokers and dual users.
Method: Twenty-six messages focusing on either harm-reduction or cessation were developed and rated by mul-
tidisciplinary experts for accuracy, persuasiveness and clarity. The eight highest ranking messages were compared 
alongside the TPD messages in a sample of 983 European residents (316 smokers, 327 non-smokers, 340 dual users) 
on understandability, believability and convincingness.
Results: On all three constructs combined, the two TPD messages rated the highest, closely followed by four relative 
risk messages “Completely switching to e-cigarettes lowers your risk of smoking related diseases”, “Use of this product 
is much less harmful than smoking”, “Completely switching to e-cigarettes is a healthier alternative to smoking”, and 
“This product presents substantially lower risks to health than cigarettes” which did not differ statistically from the 
TPD messages. Non-smokers rated TPD1 significantly higher overall than dual users. Dual users rated “This product is a 
safer alternative to smoking” significantly higher than non-smokers. Messages did not differ on understandability.
Conclusions: These alternative messages provide a useful resource for future research and for policy makers consid-
ering updating e-cigarette product labelling.
Keywords: Electronic cigarettes, E-cigarettes, Health messages, Relative risks messages, Warning labels, Tobacco 
products directive
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Background
Health warnings can increase awareness about the dan-
gers of smoking and promote cessation [1, 2] and have 
become central to anti-smoking education campaigns 
worldwide. In addition to reducing smokers’ desire 
for tobacco cigarettes [3, 4], health warnings have the 
potential to prevent initiation in non-smokers [5]. Simi-
lar labels are now displayed on electronic cigarette (EC) 
packs, usually with a focus on addictiveness. These mes-
sages are often expressed in absolute terms and do not 
contain comparative harm information which may deter 
smokers from moving to a relative risk product [6]. 
Indeed, “switching one addiction for another” is one of 
the key cited reasons for not trying an EC and percep-
tions of their risk relative to smoking is increasing [7]. 
Open Access
*Correspondence:  kimberc3@lsbu.ac.uk
1 Centre for Addictive Behaviour Research, Division of Psychology, School 
of Applied Sciences, London South Bank University, 103 Borough Road, 
London SE1 0AA, UK
Full list of author information is available at the end of the article
Page 2 of 11Kimber et al. Harm Reduct J           (2021) 18:96 
A more nuanced set of health messages may be advan-
tageous. The current study describes a comprehensive 
methodology used to develop and assess (in terms of 
understandability, believability and convincingness) a set 
of messages which highlight the relative risks of EC com-
pared to tobacco smoking.
Since their introduction, uptake and awareness of EC 
has increased [8, 9]; current use is estimated at 3.2 mil-
lion adults in Great Britain [10]. Smoking cessation and 
reduction remain the most commonly cited reasons for 
use, and there is increasing evidence for their role in 
supporting smoking abstinence [11–14]. However, ini-
tiating or increasing EC use whilst cigarette smoking is 
maintained is unlikely to lead to substantial improved 
health outcomes [15]. Despite the concerns vis-à-vis the 
increasing prevalence rates amongst youth [16, 17] and 
potential health harms specifically for users who con-
tinue to smoke concurrently [18], findings from emis-
sion, biomarker and switching studies suggest that EC 
are considerably less harmful than tobacco cigarettes [15, 
19–27], a conclusion endorsed by public health agency 
reviews [28, 29].
More recently, public misperceptions of harms associ-
ated with EC and nicotine use have increased. For exam-
ple, only 17% of UK respondents (N = 12,070) have been 
shown to correctly believe that EC are considerably less 
harmful than tobacco smoking [30]. Similarly, 32.2% 
of former and current smokers (N = 1720) in the UK 
reported that substituting tobacco cigarettes for e-cig-
arettes reduced harm to health [31]. These mispercep-
tions extend to EC addictiveness compared to smoking 
with only 25.4% perceiving the former as less addictive 
[31]. Despite widespread public health endorsement of 
EC in England such misperceptions were commonplace 
[32]. These harm misperceptions extend to other coun-
tries; only 5% of Greeks perceived EC to be less harmful 
than cigarettes [33]; 54.7% of a US sample reporting EC 
to be not at all to moderately harmful [34]; and longitu-
dinal evidence in the US suggesting a twofold increase in 
beliefs that EC are more or equally as harmful to health 
than tobacco cigarettes [35].
One likely contributory factor for such misperceptions 
may be health warnings on EC packs. In the EU, the cur-
rent regulatory framework stipulates that all EC packets 
and refill products must carry a nicotine health warning 
(“This product contains nicotine which is a highly addic-
tive substance” or “This product contains nicotine which 
is a highly addictive substance. It is not recommended 
for non-smokers”) [36], which may inflate perceptions of 
harm and addictiveness in readers. In support of this, 
studies have found the presence of a nicotine warning 
in an EC advertisement to increase risk beliefs, harm 
perceptions and addictiveness [37], and dissuade use 
intentions [38]. Similarly, in a UK sample of daily smok-
ers (N = 95), we found that exposure to the EU-TPD (EU 
Tobacco Product Directive) message reduced EC use and 
purchase intentions [6]; in a larger trial (N = 2495 UK 
residents) increased both smokers’ and non-smokers’ 
harm perceptions [39]. Similarly, focus groups with EC 
users and smokers in the US suggest that health warnings 
deemed too negative may have the unintended conse-
quence of reducing appeal among smokers who may be 
considering EC for smoking cessation [40].
Not all messaging has such effects; research suggests 
that advertising messages that have focused on differ-
ences between cigarettes and EC (e.g. helps to quit smok-
ing) rather than similarities (feels like smoking, relieves 
cravings) created more interest among smokers in trying 
an EC [41]. Moreover, whilst advertisements containing 
warnings increase addiction related risk beliefs, the con-
current presence of a EC health message (i.e. a compara-
tive risk message) nullifies this effect [42].
One way to dispel erroneous perceptions and encour-
age use of EC in smokers may be to refocus warn-
ing labels away from absolute potential harms of EC to 
ones conveying risks relative to smoking. Whilst there 
is a clear rationale for developing such messages and 
conducting initial evaluations of their effectiveness, no 
such work has been undertaken. This study aimed to (1) 
develop a set of relative risk health messages which con-
vey the relative risks of EC compared to tobacco ciga-
rettes that are believable, understandable and convincing; 
(2) compare these messages to the existing TPD nicotine 
addiction warnings currently implemented in the UK 
and in other EU countries; and (3) explore differences 
between smokers, non-smokers and dual users in how 




Drawing on our subject-specific knowledge of EC and 
with reference to (1) the general guiding principles out-
lined in the health communication message review tool 
(National Collaborating Centre for Methods and Tools 
[43]), and (2) specific recommendations for the devel-
opment of tobacco cigarette health warnings (i.e. the 
European Commission report [44], Institute of Global 
Tobacco Control [45] and the Eurobarometer Aggre-
gate Report [46]), initial messages were developed by the 
authors with a focus on the relative risk of EC vs. smok-
ing, and the benefits of completely switching to vaping. 
Given the focus here was to generate messages which 
encourage smokers to switch to a less harmful product 
rather than to develop warning messages to deter smok-
ers, the literature on cigarette health warnings was less 
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relevant. However, it was used here to inform the devel-
opment of messages in terms of possible presentation 
parameters (i.e. content, length, prominence on pack) of 
health messages that may influence the extent to which 
they will be noticed and acted upon. It is also important 
that health messages are clear, comprehensive and cred-
ible so as to increase level of attention and likelihood of 
recall [43], including for individuals with low literacy [5]. 
Twenty-six initial messages were developed incorpo-
rating a range of grammatical (second [“you” or “your”] 
and third [“they” or “smokers”]) person perspectives to 
account for the variability in which individuals attend to, 
process and respond to mass communication messages 
[47, 48]. These messages were also developed using spe-
cific versus general risk and exposure information (e. g. 
“Switching to e-cigarettes reduces damage to your lungs” 
vs. “Switching to e-cigarettes reduces your health risks” 
and “E-cigarettes reduce harmful toxin exposure to those 
around you”).
Consultation and refinement phase
To communicate health messages effectively, it is impor-
tant that messages are accurate and clear (free of techni-
cal terms and jargon) to ease readability and minimise 
cognitive effort required to engage with the materials 
[49]. One way to verify information accuracy, clarity of 
the wording and tailoring to lay audiences is to refer to 
academic knowledge and expertise. Thus, in a prelimi-
nary phase, we approached 12 experts (senior academ-
ics, behavioural scientists, health psychologists, policy 
advisors and experienced vapers; see acknowledgements 
section) in the e-cigarette, tobacco control and behaviour 
change field. Of these, 8 agreed to rate the 26 messages 
on accuracy, persuasiveness and clarity, each on a 5-point 
scale (0—not at all to 5—extremely). These experts were 
also asked to select the 3 messages that they would rec-
ommend and 3 messages that they would abandon. One 
ranking system was created for each of the reviewers for 
scores on accuracy, persuasiveness and clarity then aver-
aged and Friedman tests applied to identify the most 
highly rated, and the most and least recommended.
In the latter phase, the eight messages that scored 
the highest and were not advised by the experts to be 
abandoned were selected for further evaluation by the 
general public and rated on understandability, convinc-
ingness and believability, constructs that are likely to 
contribute to generating favourable engagement of the 
target audience, increase persuasiveness of the health 
messages [49], and in turn drive behaviour change.
Figure  1 illustrates the method used to develop and 
test the health messages. On the recommendation of 
two experts, messages were amended to add the word 
“completely” to precede the word “switching” (see 
Table  1). The list of 26 relative risk messages is pre-
sented in Table 1 (selected messages are emboldened).
Evaluation of messages by the general public
Participants and design
Participants were recruited online, largely via Figure 
Eight (an online crowd-labour platform), social media 
sites (Facebook) and a student-focused Research Partic-
ipation Scheme (RPS) at London South Bank University 
(LSBU). All measurement materials were hosted and 
delivered by Qualtrics between September and October 
2018. Payment was US$2.00 (~ €0.89) per participant 
taking part by Figure Eight or course credit for student 
participants. Of the 1,148 participants who consented 
to take part, those who failed to report their smok-
ing/vaping status (n = 140) and those who reported as 
exclusive EC users (n = 25) were excluded from all data 
analyses as they were not part of the main target sam-
ple and were not suitable for further sub-group analy-
ses due to small cell counts. The final sample of 983 
participants comprised 316 smokers, 327 non-smokers, 
340 dual users. Inclusion criteria for the study were: 
aged 18 + , resident in Europe and fluent in English. 
Participants were randomly assigned to view only one 
of the messages resulting in between 90 and 117 rat-
ings per message. A post hoc achieved power analysis 
revealed the sample was sufficient to detect (in a one-
way ANOVA design with 10 conditions, see Analysis 
below) a medium effect size (f = 0.25) with an alpha of 
0.05 at power = 0.99.
Fig. 1 Method of development and testing of relative risk health messages for electronic cigarette packs
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Materials
Eight relative risk messages (Table  1) plus two TPD 
warnings, TPD1 “This product contains nicotine which 
is a highly addictive substance” and TPD2 “This product 
contains nicotine which is a highly addictive substance. 
It is not recommended for non-smokers” received ratings 
on understandability, believability and convincingness. 
These dimensions have been used previously to evalu-
ate the efficacy of smoking cessation media messages 
[50] and EC warning statements [51]. All messages were 
displayed at the centre of the screen in black colour and 
Helvetica font bold type occupying 30% of the screen on 
a white background.
Measures
Baseline measures Demographic variables were gen-
der, age, ethnicity, occupation, economic activity and 
highest attained qualification (consistent with data col-
lected by the UK Office for National Statistics). Occu-
pation was measured with a single item comprising 
four categories: “routine and manual”, “intermediate”, 
“managerial and professional occupation”, and “never 
worked & long-term unemployed” [52].
Smoking status was recorded as “non-smoker”, “daily” 
and “occasional smoker”. EC use status was collected by 
asking: “Do you currently use an EC?” Response options 
were: “Yes, daily”, “Yes, occasionally”, “I have never used 
one”, “I used one occasionally (not daily) in the past 
and no longer use it”, and “I used one every day in the 
past and no longer use it”. For smokers, motivation to 
quit was measured using the Motivation to Stop Scale 
(MTSS), a single-item measure of intention, desire to 
stop smoking and the immediacy of quit date inten-
tion [53]. Cigarette dependence was measured using 
Table 1 Median and Mean rank for the Initial Health messages on all 3 constructs combined Accuracy, Persuasiveness and Clarity
a [EC] e-cigarettes featured in full; Bold font indicate selected messages (n = 8) further evaluated in this second phase study (N = 983); Friedman test  x2(25, 
n = 6) = 44.02, p = .011 found a significant difference on all 3 constructs combined; Friedman test  x2(25, n = 8) = 43.89 p = .011 also revealed the top 8 most 
recommended messages indicated by lower case superscript numbered 1–8; For messages to abandon, Friedman test  x2(25, n = 8) = 35.14, p = .086 found not 
significant differences but individual experts’ comments and advice on messages to “abandon” vis-à-vis the complexity and length of messages were taken into 
consideration during the selection process
Relative risk health messages Percentiles 50th median 
[25th-75th]
Mean rank
RRM1.  [EC]a are likely to be 95% less harmful than smoking 3.83 [2.58–4.67] 13.83
RRM2. [EC] reduce smoking related health risks by 95% 3.83 [2.83–4.08] 11.33
RRM3. Smoking is 95% more harmful than vaping 2.5 [1.58–3.67] 3.92
RRM4. No product is completely safe but use of this product is much less harmful than smoking 3.67 [3–4.17] 12.92
RRM5. Use of this product is much less harmful than smoking1 4.17 [3–4.75] 16.92
RRM6. No tobacco related product is safe but this product presents substantially lower risks to health than 
cigarettes
3.33 [3–3.75] 9.58
RRM7. This product presents substantially lower risks to health than cigarettes5 4.17 [3.58–4.33] 18.08
RRM8. [Completely] switching to [EC] reduces your health risks2 4 [3.5–4.33] 15.42
RRM9. [Completely] switching to [EC] reduces your cancer risk 3.83 [3.5–4.42] 15.33
RRM10. Switching to e-cigarettes improves your health 3.17 [2.5–3.67] 5
RRM11. [Completely] switching to [EC] lowers your risk of smoking related diseases6 4.17 [3.67–4.33] 17.42
RRM12. This product is a safer alternative to smoking3 4.33 [3.33–5] 20.33
RRM13. This product is a safer alternative for smokers 4.33 [3.33–5] 20.33
RRM14. Switching to [EC] reduces damage to your lungs 3.33 [3–4.5] 13.67
RRM15. Switching to [EC] reduces your chances of developing cancer 3.83 [3.58–4] 12.92
RRM16. [EC] contain no tar, the toxic component of smoke 4 [3.42–4.33] 14.92
RRM17. [EC] contain far fewer toxins than tobacco cigarettes 3.67 [3.5–4.33] 13.17
RRM18. [EC] reduce harmful toxin exposure to those around you 3.67 [3.33–3.75] 12.17
RRM19. [EC] reduce exposure to second-hand smoke 3.67 [3–4] 11.75
RRM20 Completely switching to [EC] is a healthier alternative to smoking7 3.5 [2.5–4.42] 19.75
RRM21 It is recommended that smokers should switch to [EC] 8 3.5 [2.5–4.42] 11.08
RRM22 Many smokers who switch to e-cigarettes report improved  health8 3.67 [2.92–4.17] 12.75
RRM23 Like other smokers, if you switch to e-cigarettes you will experience improved health 3.67 [2–4] 9
RRM24 Using an e-cigarette improves your chances of  quitting4 3.83 [3.25–4.33] 14.33
RRM25. Using an [EC] doubles your chances of quitting smoking8 3.33 [3.17–4.17] 11.50
RRM26. Using an [EC] reduces cravings for cigarettes 3.67 [3.25–4.08] 13.58
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the Fagerström Test for Cigarette Dependence (FTCD) 
[54].
Primary outcomes
All ten messages were rated for understandability, believ-
ability and convincingness by asking how [believable – 
understandable—convincing] the health message was. The 
response options were on Likert type scales (response 
options “Extremely = 7, Very = 6, Moderately = 5, Neu-
tral = 4, Somewhat = 3, Slightly = 2 and Not at all = 1”). 
Prior to and following the experimental exposure to one 
of the 10 EC health messages, perceptions of harmful-
ness, addictiveness and social acceptability were meas-
ured, and participants were also asked to recall the health 
message (data to be reported separately).
Statistical analysis
There were no significant associations between par-
ticipant demographics and assigned message type (all 
ps > 0.09). Descriptive statistics (mean, SD) for each mes-
sage relating to ratings of understandability, believability, 
convincingness and the total score were then obtained. 
The Cronbach alpha coefficient for the total (aggregate) 
score was 0.74. To explore differences in understandabil-
ity, believability, convincingness and the aggregate score 
between messages (10 levels) and smoking status (exclu-
sive smokers vs. non-smokers vs. dual users [concur-
rent smokers & EC users]), a two-way between-subjects 
ANOVA was conducted. As homogeneity of variances 
assumption was violated (Levene’s test p < 0.05), we con-
ducted this analysis with 1000 bootstrap samples [55]. 
Significant main effects of message and smoking status 
were explored using Bonferroni post hoc tests and signif-
icant interactions were followed up using simple effects 
analyses. The analysis was not pre-registered and the 
results should be considered exploratory.
Results
Table 2 summarises participant demographics and smok-
ing characteristics.
Aggregate ratings across understandability, believability 
and convincingness.
A main effect of message, F(9, 953) = 4.49, p = 0.001, 
ƞp2 = 0.041, was shown. TPD1, TPD2, and relative 
risk messages (RRM) 11, 5, 20 and 7 did not differ sig-
nificantly (all ps > 0.05). TPD1 and TPD2 scored signifi-
cantly higher than RRM12, RRM8 and RRM25, whilst 
RRM9 scored significantly lower than TPD1 but not 
TPD2 (see Table  3 for mean [SD] ratings for the over-
all sample and Fig. 2 for mean [SE] ratings per smoking 
status group). No main effect of smoking/vaping sta-
tus was found, F(2, 953) = 1.32, p = 0.268, ƞp2 = 0.003. A 
significant message by smoking status interaction was 
shown, F(18, 953) = 2.33, p = 0.001, ƞp2 = 0.042. Non-
smokers attributed higher scores to TPD1 compared to 
dual users (M = 6.04, 95% CI [5.66–6.42] vs. M = 5.14, 
95% CI [4.72–5.56]) p = 0.006), whilst dual users rated 
RRM12 “This product is a safer alternative to smoking” 
more favourably than non-smokers (M = 5.44, 95% CI 
[5.10–5.77] vs. M = 4.32, 95% CI [3.92–4.73]) p < 0.001).
Message understandability ratings
There were no main effect of message, [F(9, 953) = 0.88, 
p = 0.54)], smoking status [F(2, 953) = 0.81, p = 0.44] or 
message by smoking status interaction [F(18, 953) = 1.17, 
p = 0.28] for understandability (see Table 3 for mean (SD) 
and Additional file 1 for means [SE]).
Message believability ratings
Main effects for message [F(9, 953) = 6.16, p < 0.001, 
ƞp2 = 0.055)], and smoking/vaping status [F(2, 953) = 3.16, 
p = 0.04, ƞp2 = 0.007] were found. Mean believabil-
ity scores for TPD1 and TPD2 were highest followed 
by RRM11 “Completely switching to e-cigarettes lowers 
your risk of smoking related disease”, RRM5 “Use of this 
product is much less harmful than smoking” and RRM20 
“Completely switching to e-cigarettes is a healthier alter-
native to smoking”; these 5 messages did not differ statis-
tically from each other (all ps > 0.05). TPD1 was rated as 
the most believable and differed significantly from RRM7 
(p = 0.028), RRM8 (p < 0.001), RRM9 (p = 0.001), RRM12 
(p = 0.001) and RRM25 (p < 0.001). TPD2 rated second 
most believable and differing significantly from RRM8 
(p = 0.005), RRM9 (p = 0.008), RRM12 (p = 0.006) and 
RRM25 (p < 0.001). See Table 3 for mean (SD) and Addi-
tional file 2 for mean [SE] ratings.
A significant message by smoking/vaping status inter-
action [F(18, 953) = 1.78, p = 0.023, ƞp2 = 0.033] was 
shown. Dual users rated RRM12, “This product is a safer 
alternative to smoking”, as more believable (M = 5.33, 95% 
CI [4.90–5.76] compared to non-smokers (M = 4.11, 95% 
CI [3.57–4.65], p = 0.001). Smokers rated RRM5, “Use of 
this product is much less harmful than smoking”, signifi-
cantly less believable compared to dual users (M = 4.52, 
95% CI [3.98–5.05] vs. M = 5.32, 95% CI [4.88–5.75], 
p = 0.05).
Message convincingness ratings
Significant main effects for message [F(9, 953) = 5.75, 
p < 0.001, ƞp2 = 0.052], and smoking/vaping status [F(2, 
953) = 3.76, p = 0.02, ƞp2 = 0.008] were shown. The mean 
score for TPD1 (M = 5.52, 95% CI [5.24–5.79]) was the 
highest followed by TPD2 (M = 5.33, 95% CI [5.01–5.64]) 
then RRM11 “Completely switching to e-cigarettes low-
ers your risk of smoking related diseases” (M = 5.07, 95% 
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CI [4.79–5.35]) and RRM5 “Use of this product is much 
less harmful than smoking” (M = 4.89, 95% CI [4.61–
5.17]). TPD1 rated as significantly more convincing than 
all other messages (all p < 0.05) except from TPD2, and 
RRM11. RRM11 in turn, was rated as significantly more 
convincing than RRM8, RRM9, RRM12 and RRM25 
Table 2 Participants’ Characteristics
1 Countries of origin excludes missing data (n = 25) and does not sum to 100% of the sample. Only those with a frequency greater than n = 40 is shown, see 
Additional file 4: Table S1 for a more detailed list of countries; 2Smoking/Vaping status includes daily and occasional current use, 22 cases were missing; 
3FTCD = Fagerström Test for Cigarette Dependence; 4MTSS = Motivation to Stop [Smoking] Scale, both were measured in smokers only
N = 983 % Mean SD Min Max
Gender – – – – – –
Male 635 61.7 – – – –
Female 393 38.2 – – – –
Non-binary/prefer not to disclose 2 0.2 – – – –
Ethnicity – – – – – –
White 998 96.9 – – – –
Black/African/Caribbean 6 .6 – – – –
Mixed/Multiple ethnic background 13 1.3 – – – –
Asian (incl. n = 1 Other) 13 1.3 – – – –
Countries of origin1 – – – – – –
United Kingdom 142 13.8 – – – –
Ukraine 145 14.1 – – – –
Spain 94 9.1 – – – –
Italy 90 8.7 – – – –
Poland 61 5.9 – – – –
Bosnia & Herzegovina 52 5.0 – – – –
Germany 46 4.5 – – – –
Romania 46 4.5 – – – –
Other European countries 278 26.96
Occupation – – – – – –
Routine and manual 234 22.7 – – – –
Intermediate 257 25 – – – –
Managerial & professional 433 42 – – – –
Never worked & Long term unemployed 106 10.3 – – – –
Economic activity – – – – – –
Employed (incl. employed & studying) 785 76.2 – – – –
Unemployed & looking for work 96 9.3 – – – –
Unemployed & studying 50 4.9 – – – –
Retired 30 2.9 – – – –
Never worked &/or long term unemployed (incl. 
home carer)
69 6.7 – – – –
Highest qualification to date – – – – – –
Degree (or equivalent) 321 31.3 – – – –
Higher education (below degree level) 386 37.4 – – – –
A-levels or highers 129 12.5 – – – –
ONC or National level BTEC 22 2.1 – – – –
Age – – 37.81 10.60 18 83
Smoking/Vaping status2 – – – – – –
Current exclusive smokers 316 30.68 – – – –
Current Dual users 340 33.00 – – – –
Non-smokers/Non-vapers 327 31.75 – – – –
FTCD3 (N = 660) – – 3.81 2.45 0 9
MTSS4 (N = 660) – – 3.44 1.55 1 7
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Table 3 Mean (SD) per message for ratings on each subscale and the aggregate ratings
* Mean (SD) for the overall scales correspond to the aggregate ratings across understandability, believability and convincingness combined
Messages sharing a superscript letter denote significant differences (p < .05) where upper case (capital) letters indicate significantly higher rating vs. their 
corresponding lower-case letters
For example, for the main effect of message [F(9, 953) = 4.493, p = .001, ƞp2 = .041], for all subscales combined, A indicates TPD1 scored significantly higher compared 
to RRM, 8, 9, 12 and RRM25; B indicates that TPD2 scored significantly higher than RRM, 8, 12 and 25; C indicates TPD1 and 2 scored significantly higher than RRM12; D 
indicates TPD 1 and 2 scored significantly higher than RRM8; E indicates TPD1 scored significantly higher than RRM9; F indicates TPD1 and 2 scored significantly higher 
than RRM25
Messages Understandability Believability Convincingness Overall scales*
TPD1. This product contains nicotine which is a highly addictive substance 
(n = 103)
5.51 (1.76) 5.57 (1.43)A 5.52 (1.40)A 5.54 (1.24)ACDEF
TPD2. This product contains nicotine which is a highly addictive substance. It is 
not recommended for non-smokers (n = 84)
5.83 (1.48) 5.51 (1.50)B 5.33 (1.48)B 5.56 (1.38)BCDF
RRM5. Use of this product is much less harmful than smoking (n = 99) 5.49 (1.64) 5.06 (1.38) 4.89 (1.39)a 5.15 (1.13)
RRM7. This product presents substantially lower risks to health than cigarettes 
(n = 86)
 5.43 (1.41)  4.90 (1.24)a  4.81 (1.40)a  5.09 (1.15)
RRM8. Completely switching to e-cigarettes reduces your health risks (n = 98) 5.45 (1.56) 4.71 (1.46)ab 4.57 (1.46)ab 4.91 (1.16)abd
RRM9. Completely switching to e-cigarettes reduces your cancer risk (n = 113) 5.71 (1.43) 4.76 (1.54)ab 4.68 (1.55)a 5.05 (1.21)ae
RRM11. Completely switching to e-cigarettes lowers your risk of smoking related 
diseases (n = 86)
5.85 (1.20) 5.17 (1.27)C 5.07 (1.26) 5.36 (1.05)
RRM12. This product is a safer alternative to smoking (n = 111) 5.56 (1.59) 4.76 (1.44)ab 4.57 (1.42)ab 4.96 (1.17)abc
RRM20. Completely switching to e-cigarettes is a healthier alternative to smok-
ing
(n = 96) 5.64 (1.32) 5.01 (1.17) 4.85 (1.26)a 5.17 (.96)
RRM25. Using an e-cigarette doubles your chances of quitting smoking















Dual users Exclusive smokers Non-smokers/non-vapers Overall sample
Fig. 2 Overall mean (SE) ratings across all constructs combined per group and for the overall sample
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(p < 0.05). See Table 3 for mean (SD) and Additional file 3 
for mean (SE) ratings.
A significant message by smoking/vaping status inter-
action [F(18, 953) = 2.49, p = 0.001, ƞp2 = 0.045] was 
shown. Non-smokers rated TPD1 as more convincing 
and RRM25, “Using an e-cigarette doubles your chances 
of quitting smoking”, as less convincing compared to dual 
users (TPD1: M = 5.00, 95% CI [4.52–5.48] vs. M = 6.16, 
95% CI [5.78–6.54], p = 0.001; RRM25: M = 4.20, 95% CI 
[4.08–5.05] vs. M = 5.29, 95% CI [4.92–5.65], p = 0.005). 
Non-smokers rated RRM12, “This product is a safer alter-
native to smoking”, as less convincing than dual users 
(M = 3.78, 95% CI [3.29–4.258] vs. M = 5.21, 95% CI 
[4.82–5.59], p < 0.001) and smokers (M = 4.69, 95% CI 
[4.27–5.10], p = 0.012).
Discussion
Current health warnings, such as those implemented by 
the TPD, may inadvertently deter smokers from initiating 
EC use and substituting their smoking for vaping due to 
their sole emphasis on the potential health-related harms 
of nicotine [6, 32]. This may be problematic to the extent 
that, for smokers, EC have been shown to be more effica-
cious than nicotine replacement therapies [13] as well as 
useful tools to prevent relapse [56]. One way to encour-
age smokers to use EC to promote a switch away from 
smoking may be to refocus warning labels away from 
absolute potential harms to ones conveying risks relative 
to smoking. In this paper, we describe the development 
of a set of eight alternative health messages for EC pack-
ages and the testing of these messages against the current 
TPD warning messages on understandability, believ-
ability and convincingness. We also present differences 
between smokers, non-smokers and dual users.
From 26 original messages, we explored perceived 
understandability, believability and convincingness of 
the 8 relative risks messages most highly rated by experts 
and 2 current TPD messages. The two current TPD mes-
sages were consistently rated the highest for combined 
understandability, believability and convincingness rat-
ing, but did not differ significantly from four relative risk 
messages; “Completely switching to e-cigarettes lowers 
your risk of smoking related diseases” (RRM11), “Use of 
this product is much less harmful than smoking” (RRM5), 
“Completely switching to e-cigarettes is a healthier alter-
native to smoking” (RRM20), and “This product pre-
sents substantially lower risks to health than cigarettes” 
(RRM7). In terms of the distinct dimension ratings, all 
messages were rated highly on “understandable”. Impor-
tantly, we did not detect a difference between relative 
risk messages and the TPD messages in this domain; 
mean ratings were all above 5 indicating that they were 
as understandable as the current TPD standard. The 
messages that scored the highest on “believable” and 
“convincing” were RRM11 and RRM5 alongside the two 
TPD messages. Compared to dual users, non-smokers 
attributed higher scores to TPD1 (which emphasises 
nicotine addiction), whilst dual users rated RRM12, “This 
product is a safer alternative to smoking”, more favourably 
than non-smokers.
What may explain the observation that the TPD 
received the highest ratings compared to the relative risk 
messages overall? One possibility regarding believabil-
ity may be due to pre-existing beliefs around the health 
risks and addictive properties of nicotine. There are many 
examples in the literature demonstrating public mis-
perceptions of the harms of nicotine [32]. In one online 
survey, smokers reported beliefs that very low nicotine 
cigarettes were less carcinogenic [57] whilst only 8.6% 
of a UK sample had accurate harm perceptions, that is, 
a very small amount of the harm of smoking comes from 
nicotine [58]. Our own recent work has shown TPD mes-
sages were associated with greater addictiveness and 
harm perceptions of EC especially in non-smokers/non-
EC users [39]. Hence, the nicotine addiction warning 
conveyed by the TPD may align with current tobacco and 
nicotine beliefs.
Another explanation for the higher endorsement of 
the TPD as the most believable and convincing could 
be due to previous exposure. It is plausible that through 
repeated exposure, this familiarity may enhance message 
credibility and acceptability [59]. It is highly encouraging 
that despite the lack of familiarity with the relative risk 
messages, four messages did not statistically differ from 
the TPD messages. However, this also means that a famil-
iarity explanation is not sufficient in isolation. Indeed, 
it could be argued that because novelty requires greater 
cognitive demand, new, unfamiliar content may increase 
attention to these messages. Regardless of preferred 
explanation, that these messages were rated as favourably 
as the TPD in a sizeable European sample, suggests that 
such relative risk messages have equal persuasive poten-
tial and good utility for future studies exploring how best 
to communicate the relative risks of EC on EC packs.
Importantly, our data did not indicate that these rela-
tive risk messages would lead to unintended conse-
quences in non-smokers. Consistent with our previous 
findings [39] and those of others [31, 60, 61], non-smok-
ers were more likely to endorse the TPD messages. More 
specifically, non-smokers ascribed greater believability 
and convincingness to the TPD1 compared to dual users, 
whilst dual users tended to rate the relative risk mes-
sages (i.e. “This product is a safer alternative to smoking”) 
more favourably in comparison to non-smokers and (i.e. 
“Use of this product is much less harmful than smoking”) 
compared to smokers. That non-smokers were less likely 
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to endorse the relative risks messages compared to dual 
users may possibly be an artefact of the study given that 
these were not government-mandated warning labels 
which may have had an impact on their credibility. How-
ever, importantly this suggests that non-smokers may be 
less receptive to such messages. This is important inso-
much that persuasive health messaging on EC packag-
ing should not deter smokers to switch to reduced risk 
products whilst not enticing non-smokers. One possi-
ble explanation for the higher ratings of the relative risk 
messages in dual users compared to smokers may be that 
they are better informed about EC relative risks due to 
their experience of using the product [62]; or it is also 
possible that because they are invested and involved, they 
may have been more attentive to these messages thereby 
more likely to endorse them [63]. Thus, ways of enhanc-
ing the credibility of relative risk messages certainly war-
rants further investigation. Because such relative risk 
messages (“Use of this product is much less harmful than 
smoking” RRM5) are more likely to increase use inten-
tions in smokers than non-smokers [39], they hold prom-
ise for further empirical investigation.
Whilst the current paper focuses on the develop-
ment of the messages, it does not determine the extent 
to which these messages correct misperceptions and 
increase knowledge around harms of nicotine and EC; 
this could be the focus for future research. It would be 
useful to evaluate the universality of these messages by 
testing them in different regulatory environments out-
side of the EU as well as in developing countries with 
high smoking prevalence. Future work could also evalu-
ate these relative risk messages’ persuasiveness potential 
further by testing their legibility (fonts, colour, font size, 
positioning and prominence on the pack, background 
contrast, and so on), readability, memorability and per-
ceptual fluency (how easily and favourably they can be 
processed and evaluated).
The method used here presents some potential limi-
tations. Although a reasonable sample size was used, 
a little above 10% were based in the UK and the vast 
majority were from other European countries. It is, 
therefore, possible that the results were influenced by 
differential past exposure and familiarity with the TPD 
messages. It is worth noting that our analyses did not 
include exclusive EC users. Given dual users showed 
greater endorsement of the relative risk messages com-
pared to smokers, these ratings could have been even 
higher had exclusive EC users been included. A fur-
ther possible limitation is the over-representation of 
individuals from managerial and professional groups 
over those from routine and manual occupations given 
that smoking is largely concentrated in the latter as 
opposed to the former groups. Whilst useful, findings 
are confined to intentions and do not explore changes 
or fluctuations in perceptions or, how intentions trans-
late into behaviours.
Conclusions
Here, we present the phased method that allowed the 
development of eight messages initially selected from 
a series of 26 rated by a panel of experts and thereafter, 
rated by the general public in a European sample. Find-
ings from this study are of relevance for public health as 
they may benefit the understanding of how best to com-
municate relative health risks associated with EC. These 
relative risk messages are intended for use by regula-
tors and policy-makers as alternative messages to cur-
rent heath messages on EC packs. We encourage other 
researchers to further explore their usefulness and effects 
on perceptions and/or intentions in different populations 
and settings.
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